Madrigal Pharmaceuticals Valuation
| MDGL Stock | USD 331.45 5.29 1.57% |
At this time, the firm appears to be overvalued. Madrigal Pharmaceuticals secures a last-minute Real Value of $286.73 per share. The latest price of the firm is $331.45. Our model forecasts the value of Madrigal Pharmaceuticals from analyzing the firm fundamentals such as Operating Margin of (1.87) %, shares outstanding of 21.81 M, and Return On Equity of -1.3 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Madrigal Pharmaceuticals' valuation include:
Price Book 9.4504 | Enterprise Value 6.5 B | Enterprise Value Ebitda (8.32) | Price Sales 95.6145 | Enterprise Value Revenue 84.1648 |
Overvalued
Today
Please note that Madrigal Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Madrigal Pharmaceuticals is based on 3 months time horizon. Increasing Madrigal Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Madrigal stock is determined by what a typical buyer is willing to pay for full or partial control of Madrigal Pharmaceuticals. Since Madrigal Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Madrigal Stock. However, Madrigal Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 331.45 | Real 286.73 | Target 318.25 | Hype 326.9 | Naive 305.5 |
The intrinsic value of Madrigal Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Madrigal Pharmaceuticals' stock price.
Estimating the potential upside or downside of Madrigal Pharmaceuticals helps investors to forecast how Madrigal stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Madrigal Pharmaceuticals more accurately as focusing exclusively on Madrigal Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Madrigal Pharmaceuticals' intrinsic value based on its ongoing forecasts of Madrigal Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Madrigal Pharmaceuticals' closest peers.
Madrigal Pharmaceuticals Cash |
|
Madrigal Valuation Trend
Knowing Madrigal Pharmaceuticals' actual value is paramount for traders when making sound investment determinations. Using both Madrigal Pharmaceuticals' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Madrigal Pharmaceuticals Total Value Analysis
Madrigal Pharmaceuticals is now forecasted to have valuation of 6.46 B with market capitalization of 7.34 B, debt of 117.19 M, and cash on hands of 211.77 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Madrigal Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
6.46 B | 7.34 B | 117.19 M | 211.77 M |
Madrigal Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Madrigal is to check how much profit was generated for every dollar of assets it reports. Madrigal Pharmaceuticals secures a negative usage of assets of -0.52 %, losing $0.005225 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Madrigal Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Madrigal Pharmaceuticals Ownership Allocation
The majority of Madrigal Pharmaceuticals outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Madrigal Pharmaceuticals to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Madrigal Pharmaceuticals. Please pay attention to any change in the institutional holdings of Madrigal Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.Madrigal Pharmaceuticals Profitability Analysis
Net Loss for the year was (373.63 M) with profit before overhead, payroll, taxes, and interest of 0.About Madrigal Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Madrigal Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Madrigal Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Madrigal Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Madrigal Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Madrigal Pharmaceuticals. We calculate exposure to Madrigal Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Madrigal Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -527 K | -500.6 K | |
| Pretax Profit Margin | (491.21) | (466.65) | |
| Operating Profit Margin | (476.75) | (452.91) | |
| Net Loss | (491.21) | (466.65) |
Madrigal Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Madrigal Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 18.7 M |
Madrigal Pharmaceuticals Current Valuation Indicators
Madrigal Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Madrigal Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Madrigal Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Madrigal Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Madrigal Pharmaceuticals' worth.When determining whether Madrigal Pharmaceuticals is a strong investment it is important to analyze Madrigal Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Madrigal Pharmaceuticals' future performance. For an informed investment choice regarding Madrigal Stock, refer to the following important reports: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.02) | Revenue Per Share 3.705 | Return On Assets (0.52) | Return On Equity (1.30) |
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.